Cargando…

Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis

INTRODUCTION: Medical cannabis (MC) is commonly claimed to be an effective treatment for chronic or refractory pain. With interest in MC in the United States growing, as evidenced by the 29 states and 3 US districts that now have public MC programs, the need for clinical evidence supporting this cla...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellnier, Terrance, Brown, Geoffrey W., Ortega, Tulio R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: College of Psychiatric & Neurologic Pharmacists 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007634/
https://www.ncbi.nlm.nih.gov/pubmed/29955555
http://dx.doi.org/10.9740/mhc.2018.05.110
_version_ 1783333072691789824
author Bellnier, Terrance
Brown, Geoffrey W.
Ortega, Tulio R.
author_facet Bellnier, Terrance
Brown, Geoffrey W.
Ortega, Tulio R.
author_sort Bellnier, Terrance
collection PubMed
description INTRODUCTION: Medical cannabis (MC) is commonly claimed to be an effective treatment for chronic or refractory pain. With interest in MC in the United States growing, as evidenced by the 29 states and 3 US districts that now have public MC programs, the need for clinical evidence supporting this claim has never been greater. METHODS: This was a retrospective, mirror-image study that investigated MC's effectiveness in patients suffering from chronic pain associated with qualifying conditions for MC in New York State. The primary outcome was to compare European Quality of Life 5 Dimension Questionnaire (EQ-5D) and Pain Quality Assessment Scale (PQAS) scores at baseline and 3 months post-therapy. The secondary outcomes included comparisons of monthly analgesic prescription costs and opioid consumption pre- and post-therapy. Tolerability was assessed by side effect incidence. RESULTS: This investigation included 29 subjects. Quality of life and pain improved, measured by change in EQ-5D (Pre 36 – Post 64, P < .0001) and change in PQAS paroxysmal (Pre 6.76 – Post 2.04, P < .0001), surface (Pre 4.20 – Post 1.30, P < .0001), deep (Pre 5.87 – Post 2.03, P < .0001), unpleasant (Pre “miserable” – Post “annoying”, P < .0001). Adverse effects were reported in 10% of subjects. DISCUSSION: After 3 months treatment, MC improved quality of life, reduced pain and opioid use, and lead to cost savings. Large randomized clinical trials are warranted to further evaluate the role of MC in the treatment of chronic pain.
format Online
Article
Text
id pubmed-6007634
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher College of Psychiatric & Neurologic Pharmacists
record_format MEDLINE/PubMed
spelling pubmed-60076342018-06-28 Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis Bellnier, Terrance Brown, Geoffrey W. Ortega, Tulio R. Ment Health Clin Original Research INTRODUCTION: Medical cannabis (MC) is commonly claimed to be an effective treatment for chronic or refractory pain. With interest in MC in the United States growing, as evidenced by the 29 states and 3 US districts that now have public MC programs, the need for clinical evidence supporting this claim has never been greater. METHODS: This was a retrospective, mirror-image study that investigated MC's effectiveness in patients suffering from chronic pain associated with qualifying conditions for MC in New York State. The primary outcome was to compare European Quality of Life 5 Dimension Questionnaire (EQ-5D) and Pain Quality Assessment Scale (PQAS) scores at baseline and 3 months post-therapy. The secondary outcomes included comparisons of monthly analgesic prescription costs and opioid consumption pre- and post-therapy. Tolerability was assessed by side effect incidence. RESULTS: This investigation included 29 subjects. Quality of life and pain improved, measured by change in EQ-5D (Pre 36 – Post 64, P < .0001) and change in PQAS paroxysmal (Pre 6.76 – Post 2.04, P < .0001), surface (Pre 4.20 – Post 1.30, P < .0001), deep (Pre 5.87 – Post 2.03, P < .0001), unpleasant (Pre “miserable” – Post “annoying”, P < .0001). Adverse effects were reported in 10% of subjects. DISCUSSION: After 3 months treatment, MC improved quality of life, reduced pain and opioid use, and lead to cost savings. Large randomized clinical trials are warranted to further evaluate the role of MC in the treatment of chronic pain. College of Psychiatric & Neurologic Pharmacists 2018-04-26 /pmc/articles/PMC6007634/ /pubmed/29955555 http://dx.doi.org/10.9740/mhc.2018.05.110 Text en © 2018 CPNP. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Bellnier, Terrance
Brown, Geoffrey W.
Ortega, Tulio R.
Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis
title Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis
title_full Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis
title_fullStr Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis
title_full_unstemmed Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis
title_short Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis
title_sort preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007634/
https://www.ncbi.nlm.nih.gov/pubmed/29955555
http://dx.doi.org/10.9740/mhc.2018.05.110
work_keys_str_mv AT bellnierterrance preliminaryevaluationoftheefficacysafetyandcostsassociatedwiththetreatmentofchronicpainwithmedicalcannabis
AT browngeoffreyw preliminaryevaluationoftheefficacysafetyandcostsassociatedwiththetreatmentofchronicpainwithmedicalcannabis
AT ortegatulior preliminaryevaluationoftheefficacysafetyandcostsassociatedwiththetreatmentofchronicpainwithmedicalcannabis